Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: Seeking Alpha
Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela's net revenues in Q4 2023. Trilaciclib's further successful development and commercialization are crucial for GTHX's valuation and future revenue streams, and early trials suggest that it is effective. Despite cash burn and dilution concerns, I rate GTHX a speculative "buy" due to its promising revenue growth and product pipeline. G1 Therapeutics, Inc. ( NASDAQ: GTHX ) is a commercial-stage biopharmaceutical company specializing in developing and commercializing advanced oncology treatments. Its flagship product, Cosela (Trilaciclib), is an FDA-approved drug for reducing chemotherapy side effects like myelosuppression in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC),
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024GlobeNewswire
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
GTHX
Earnings
- 2/28/24 - Beat
GTHX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- GTHX's page on the SEC website